JDRF Partners with EOFlow to Develop Wearable...

[mannmade]

markets.businessinsider.com/news/stocks/JDRF-Partners-with-EOFlow-to-Develop-Wearable-Automated-Insulin-Delivery-System-for-People-with-Type-1-Diabetes-1013995743

JDRF Partners with EOFlow to Develop Wearable Automated Insulin Delivery System for People with Type 1 Diabetes
PRESS RELEASE PR Newswire
Jan. 25, 2018, 08:47 AM
NEW YORK and SEOUL, South Korea, Jan. 25, 2018 /PRNewswire-USNewswire/ -- JDRF, the global leading organization funding type 1 diabetes (T1D) research, is pleased to announce a new Industry Development and Discovery Partnership supporting South Korea's EOFlow Co., Ltd. in the development of a wearable, disposable automated insulin delivery patch device for people with T1D.

JDRF (PRNewsFoto/JDRF)

EOFlow recently received Korean Ministry of Food and Drug Safety (MFDS) approval on its wearable insulin pump system, EOPatch. The product incorporates a proprietary electroosmotic pumping technology which allows it to be smaller and lighter and the company plans to build on this strength to create a small, light and wearable automated insulin delivery device suitable for children's use.

"JDRF is working hard to reduce the burden of living with type 1 diabetes while we search for ways to cure this disease," said Jaime Giraldo, Ph.D., JDRF Research Scientist. "Innovation in automated insulin delivery devices and artificial pancreas (AP) systems will help to significantly improve health and quality of life for people with T1D. Next-generation wearable designs that are smaller and employ user-centric design will remove barriers that prevent some people, especially small children, from using these life-saving and life-changing glucose management devices."

"We are very excited that EOFlow is partnering with the world's leading private nonprofit funder of T1D research to accelerate the development of this wearable automated insulin delivery system. JDRF is a partner that believes in our vision of a small, practical, fully functional artificial pancreas system that can be used by anyone with T1D to help live a fuller life," said EOFlow Chief Executive Officer Jesse Kim.

EOFlow will use the funding to develop and run clinical studies on the wearable device, which consists of an insulin pump and an integrated continuous glucose sensor, which is run by a closed-loop program that autonomously regulates the blood glucose level with minimal user input. This is the first time JDRF is granting funds to EOFlow for research and is also the first time that JDRF is funding a company in Korea.

Since JDRF launched the Artificial Pancreas Project more than a decade ago, significant progress has been made in automating insulin delivery. However, a major factor when considering AP therapy is that the system becomes a major part of the life of a person with T1D. Currently, AP system hardware is bulky and either in direct contact, tethered to, or in very close proximity to the body, which may be barriers to the subsequent widescale adoption of AP systems. This factor is especially compounded in children, where skin real estate is at a premium. JDRF wishes to reduce obstacles preventing AP system use for people with diabetes, in part by reducing on-body burden. In addition, now that AP systems have been consistently demonstrating sufficient safety and efficacy, user centric design is becoming an important consideration to be addressed in next-generation AP systems. These ease-of-use factors include minimizing the number of steps to fill, replace and install AP system components; integrating various AP system components into a single device to reduce the burden of managing disparate components at different intervals; and the size of the wearable devices.

About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @jdrf.

About EOFlow Inc.
EOFlow is a Korea based wearable medical device company founded in 2011, developing several innovative drug delivery systems based on its proprietary electro-osmosis pumping technology. The Company's first product is EOPatch, the world's lightest and safest fully functional wearable, disposable insulin pump for people with diabetes. For more information please visit us at www.eoflow.com or follow us on Twitter: @eopatch.

[dreamboatcruise]

Hmmm... website is down.

[agedhippie]

Jan 26, 2018 18:26:21 GMT -5 dreamboatcruise said:

Hmmm... website is down.

You have exceeded your daily contracted traffic amount. Perhaps they could spring for better hosting with some of the funding 

[dreamboatcruise]

Jan 26, 2018 19:03:18 GMT -5 agedhippie said:

Jan 26, 2018 18:26:21 GMT -5 dreamboatcruise said:

Hmmm... website is down.

You have exceeded your daily contracted traffic amount. Perhaps they could spring for better hosting with some of the funding 

Yes, perhaps. 

Though now it seems to be back up.  I'm sure it's me. or not

[sayhey24]

Al Mann said many times the solution for T2s was afrezza and for T1s the patch pump and afrezza. With Treshiba there is less need for the patch but no less need for afrezza.

[agedhippie]

Jan 27, 2018 10:30:31 GMT -5 sayhey24 said:

Al Mann said many times the solution for T2s was afrezza and for T1s the patch pump and afrezza. With Treshiba there is less need for the patch but no less need for afrezza.

You cannot do this with Tresiba (not my results btw.) You would see a dip around 2am to 3 am and a rise from about 5am onwards. Doing this takes a pump.

[dreamboatcruise]

agedhippie... do you feel there is benefit to having BG that flat. I don't think people without diabetes normally have such a flat line.

[agedhippie]

Jan 27, 2018 17:02:50 GMT -5 dreamboatcruise said:

agedhippie ... do you feel there is benefit to having BG that flat. I don't think people without diabetes normally have such a flat line.

Mostly there is no benefit. It's impressive though!

People naturally have low basal output in the early hours of the morning, and have a rise starting just before dawn. In a non-diabetic the rise is minimal because the body steps up the output of insulin to absorb the rise which in turn provides you with the energy to get out of bed and wrestle a bear to the floor (it was a survival trait to be alert when you woke up).

Because of their diabetes diabetics don't absorb the dawn glucose though and consequently go high - it's a great start to the day! The fact they have nailed that dawn rise so tightly is impressive and means they start where a non-diabetic would. You cannot do this Lantus, Tresiba, Toujeo, or any injected basal.

[sayhey24]

If you can get close with Tresiba is it worth the hassle of the pump? I doubt it. Not only that but the challenge is not during resting periods its post meal and stopping the spike and getting back to baseline.

In the U.S. the entire T1 market is only 1.5M when compared to 100M in the afrezza target market. From an afrezza perspective I could care less if they are using a pump, the patch or Tresiba. They should all be taking afrezza too. If it were me I would probably take the patch over tresiba and tresiba over the pump. I guess Al thought the same and he was always ahead of the pack.

Anyway you look at it once afrezza catches on its really going to squeeze the basal market as the T2s will never "Graduate" to it and that is BPs biggest basal market not the T1s. The pump will become a real niche business. I think Al said it would become obsoleted and he is probably right again.

[agedhippie]

Jan 27, 2018 18:04:58 GMT -5 sayhey24 said:

If you can get close with Tresiba is it worth the hassle of the pump? I doubt it. Not only that but the challenge is not during resting periods its post meal and stopping the spike and getting back to baseline.

In the U.S. the entire T1 market is only 1.5M when compared to 100M in the afrezza target market. From an afrezza perspective I could care less if they are using a pump, the patch or Tresiba. They should all be taking afrezza too. If it were me I would probably take the patch over tresiba and tresiba over the pump. I guess Al thought the same and he was always ahead of the pack.

Anyway you look at it once afrezza catches on its really going to squeeze the basal market as the T2s will never "Graduate" to it and that is BPs biggest basal market not the T1s. The pump will become a real niche business. I think Al said it would become obsoleted and he is probably right again.

The patch is a pump, and yes it is worth doing because it puts your basal on auto pilot - it just happens.

For Afrezza to squeeze basal insulin you need the standard of care to change so prandial insulin doesn't have to wait for the third treatment phase, and that is not happening any time soon.

[sayhey24]

We will see. We knew CGMs and the Cloud were coming but few expecting them to move as fast as they did in the last year. I think you said the same about them this time last year if I remember correctly - "not happening any time soon".

All MNKD needs is the first big Cloud monitoring company like Onduo to follow a similar protocol as VDex's. With Edelman developing the protocol there is a chance. If not someone will, otherwise it will take an extra year as VDex grows and starts making some noise.

All it will take is one. Who wants to be the first to do more than monitor? Maybe Sam the Care Lead at Onduo would rather say "Awesome - I saw you took your afrezza with breakfast and stopped the spike and you are running non-diabetic numbers - Great Job" www.onduo.com

[mango]

Jan 28, 2018 10:35:37 GMT -5 agedhippie said:

Jan 27, 2018 18:04:58 GMT -5 sayhey24 said:

If you can get close with Tresiba is it worth the hassle of the pump? I doubt it. Not only that but the challenge is not during resting periods its post meal and stopping the spike and getting back to baseline.

In the U.S. the entire T1 market is only 1.5M when compared to 100M in the afrezza target market. From an afrezza perspective I could care less if they are using a pump, the patch or Tresiba. They should all be taking afrezza too. If it were me I would probably take the patch over tresiba and tresiba over the pump. I guess Al thought the same and he was always ahead of the pack.

Anyway you look at it once afrezza catches on its really going to squeeze the basal market as the T2s will never "Graduate" to it and that is BPs biggest basal market not the T1s. The pump will become a real niche business. I think Al said it would become obsoleted and he is probably right again.

The patch is a pump, and yes it is worth doing because it puts your basal on auto pilot - it just happens.

For Afrezza to squeeze basal insulin you need the standard of care to change so prandial insulin doesn't have to wait for the third treatment phase, and that is not happening any time soon.

What we know is that people with T2D have a loss of the first-phase insulin response and basal insulin therapy cannot restore this nor address post-prandial hyperglycemia. If we want to stop beta-cell failure as early as possible then the ADA will need to stop playing games. 

In the case of T2D, we need a prandial insulin not a basal insulin. Recommending and/or prescribing basal insulin to people with T2D is medically incorrect. No other insulin mimics endogenous prandial insulin secretion more closely than Afrezza. The FPIR is vital in the regulation of glucose homeostasis. What is needed is Afrezza and I see no use for any of the injectable prandial insulins because they do not solve a problem. Afrezza solves a problem—it restores the FPIR. 

[mango]

Jan 28, 2018 10:35:37 GMT -5 agedhippie said:

Jan 27, 2018 18:04:58 GMT -5 sayhey24 said:

If you can get close with Tresiba is it worth the hassle of the pump? I doubt it. Not only that but the challenge is not during resting periods its post meal and stopping the spike and getting back to baseline.

In the U.S. the entire T1 market is only 1.5M when compared to 100M in the afrezza target market. From an afrezza perspective I could care less if they are using a pump, the patch or Tresiba. They should all be taking afrezza too. If it were me I would probably take the patch over tresiba and tresiba over the pump. I guess Al thought the same and he was always ahead of the pack.

Anyway you look at it once afrezza catches on its really going to squeeze the basal market as the T2s will never "Graduate" to it and that is BPs biggest basal market not the T1s. The pump will become a real niche business. I think Al said it would become obsoleted and he is probably right again.

The patch is a pump, and yes it is worth doing because it puts your basal on auto pilot - it just happens.

For Afrezza to squeeze basal insulin you need the standard of care to change so prandial insulin doesn't have to wait for the third treatment phase, and that is not happening any time soon.

Afrezza should be the only insulin recommended because it most closely mimics endogenous prandial insulin secretion and it restores the FPIR—all other prandial insulins cannot do this because they are much too slow and last much too long.

People with T2D will not get the same results and outcomes using different prandial insulins. The kinetics of injectable prandial insulins are just no where near that of Afrezza, so recommending prandial insulins as one therapy bunched together as different options that delivery the same results would be lying and deceitful.

And since the number 1 most important thing here is to address the progressive beta-cell failure, then we shouldn't be putting people on anything that does not solve this problem. Afrezza solves this problem. Loss of the FPIR is the first thing to go in people with T2D and basal insulin does not restore this nor fix the dysregulation in post-prandial glucose homeostasis (due to the loss of the FPIR) in any way. 

Basal insulin—"Well, that is medically incorrect."
—Al Mann

[sayhey24]

Basal insulin—"Well, that is medically incorrect." Great Quote.

As I remember it the patch pump which Al envisioned was the next generation of the V-Go which would be similar to the Libre in size and care required. That ain't GrandMa's pump.

Now for afrezza to squeeze basal insulin all we need is one company like Amazon to understand Diabetes is a huge expense and time is money and times is over for more studies which tell us afrezza mimics a healthy pancreas and is the only way to "stop the spike". What studies are in the hopper which will again tell us the same? STAT and OneDrop?

[dreamboatcruise]

Jan 30, 2018 20:01:17 GMT -5 sayhey24 said:

Basal insulin—"Well, that is medically incorrect." Great Quote.

As I remember it the patch pump which Al envisioned was the next generation of the V-Go which would be similar to the Libre in size and care required. That ain't GrandMa's pump.

Now for afrezza to squeeze basal insulin all we need is one company like Amazon to understand Diabetes is a huge expense and time is money and times is over for more studies which tell us afrezza mimics a healthy pancreas and is the only way to "stop the spike". What studies are in the hopper which will again tell us the same? STAT and OneDrop?

Where did he say that?  That could one day be proven correct.  Just wondering when/where he actually said that.  I've followed for a long time and don't remember that particular statement.